CSIMarket
 
Entasis Therapeutics Holdings Inc   (ETTX)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 48
 Employees 25
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -52
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 0

Entasis Therapeutics Holdings Inc
Entasis Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company that is focused on developing novel, breakthrough treatments for serious bacterial infections. The company's mission is to address the urgent need for new drugs to treat drug-resistant infections, which are responsible for thousands of deaths each year.

Founded in 2015 in Waltham, Massachusetts, Entasis Therapeutics Holdings Inc has since become recognized as a leader in the field of anti-infectives. The company's team of experts have a deep understanding of bacterial pathogens, and use that knowledge to design and develop innovative therapies that target the underlying mechanism of antibiotic resistance.

Entasis Therapeutics Holdings Inc is dedicated to developing novel treatments for serious bacterial infections that have been designated by the World Health Organization as priority pathogens. These include multidrug-resistant Gram-negative bacteria such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae (including Klebsiella pneumoniae and Escherichia coli) as well as infections caused by the Gram-positive Staphylococcus aureus.

The company's pipeline includes multiple potential new therapies in various stages of development. Its lead product candidate, zoliflodacin, is a first-in-class oral antibiotic that targets the bacterial enzyme DNA gyrase, promising a new option for the treatment of uncomplicated gonorrhea. Zoliflodacin received the prestigious Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA).

Another product candidate in pre-clinical development, ETX0282CPDP, is a potent inhibitor of the bacterial enzyme LpxC, which plays a critical role in the biosynthesis of the bacterial cell wall. ETX0282CPDP demonstrates activity against a wide range of Gram-negative bacteria, including those resistant to multiple antibiotics.

Entasis Therapeutics Holdings Inc works collaboratively with various organizations, including academic institutions, government agencies, and pharmaceutical companies to accelerate the development of its pipeline products. The company is committed to addressing the global public health crisis of antibiotic resistance, by creating new, effective therapies that can help patients fight serious infections, while also preserving the efficacy of existing therapies over time.


   Company Address: 35 Gatehouse Drive Waltham 2451 MA
   Company Phone Number: 810-0120   Stock Exchange / Ticker: NASDAQ ETTX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Altimmune Inc

Altimmune Inc Faces Financial Setback: Net Loss Deepens in Fourth Quarter of 2023

Altimmune Inc., a clinical-stage biopharmaceutical company, has recently reported its financial results for the three months ending December 31, 2023. It recorded a loss per share of $-0.50, which is an increase from the loss of $-0.46 per share in the previous year's reporting period. In the preceding reporting period, Altimmune Inc. realized a loss per share of $-0.39. Alongside this, the company witnessed a significant decline in revenue, with a decrease of -89.779% from $0.36 million to an alarming level. This decline in revenue was accompanied by a surge in losses.
The net loss for the fourth quarter of 2023 amounted to $-31.641 million, higher than the $-21.660 million reported in the same quarter a year ago. Additionally, Altimmune Inc. reported a net deficit of $-88.45 million for the 2023 financial year, with revenue reaching just $0.43 million.

Cellectar Biosciences Inc

Cellectar Biosciences Inc. Stock Soars as Positive Market Sentiment Prevails

Cellectar Biosciences Inc, a late-stage clinical biopharmaceutical company focused on cancer treatment, has seen its stock rise by 20.9% over the last five trading days. This significant increase in stock value indicates a positive market sentiment towards the company. Moreover, over the past 12 months, the stock has shown a continuous upward trend, coming within 9% of its 52-week high.
These positive market indicators could be attributed to recent developments within the company. Cellectar Biosciences announced through a press release that it has achieved positive findings from an investigator-initiated Phase 1 study. The study evaluated the safety and efficacy of Iopofosine in combination with external beam radiotherapy (EBRT) for the treatment of recurrent head and neck cancer. This groundbreaking research has created a sense of hope for both patients and healthcare professionals who are seeking improved therapeutic options for this challenging disease.

Glycomimetics Inc

2. GlycoMimetics Inc Reports $0.01 Million in Revenue for Q4 2023 Financial Report



GlycoMimetics, a prominent biotechnology company headquartered in Rockville, Maryland, recently made headlines with the approval of an inducement grant for its new Senior Vice President, Dr. Shantha Tyavanagimatt. This article delves into the details of the grant and its potential implications on GlycoMimetics' shares. Additionally, we will analyze the recent performance of Glycomimetics Inc shares and provide context to understand the broader market trends.
Grant Approval:
On February 6, 2024, GlycoMimetics' Compensation Committee granted Dr. Shantha Tyavanagimatt an option to purchase 130,000 shares of the company's common stock. This inducement equity award aims to attract and retain highly qualified professionals in crucial leadership positions, thereby strengthening GlycoMimetics' technical operations.

Ampio Pharmaceuticals Inc

Investors Impressed by Ampio Pharmaceuticals Inc.'s Operating Loss Improvement in Q4 2023



Investors have been pleasantly surprised by recent developments in the stock market, particularly in the healthcare sector. Ampio Pharmaceuticals Inc. (AMPE) has showcased encouraging numbers during the October to December 2023 earnings season. Despite expectations of no significant changes at the top-line, the company's operating loss has improved, hinting at a positive trajectory for future success. Shareholders and market participants are gaining confidence in AMPE's potential, and these promising developments are worth exploring in detail.
Operating Loss Improvement:
During the same period, AMPE displayed a noteworthy reduction in operating loss, from $-2.702 million in Q4 of 2022 to $-2.215 million currently. While it may not be the easiest benchmark, this improvement is substantial and indicative of the company's commitment to growth and stability. Moreover, the company has further narrowed the losses from $-2.220 million to $-2.054 million quarter-on-quarter, boosting expectations of its future performance.

Vaxxinity Inc

VAXX Reports Earnings for Fiscal Period Ending December 31, 2023, Amid Industry Analysis

The Major Pharmaceutical Preparations sector researchers have recently begun analyzing the fourth quarter performance of 2023. One company in particular, Vaxxinity Inc, has caught their attention due to its operating shortfall of $-25.05 million for the period. It is worth noting that Vaxxinity Inc has not yet reported its top-line figures for this reporting season.
To provide some context, let's compare this performance to the previous year. In the fourth quarter of 2022, Vaxxinity Inc reported an operating shortfall of $-20.823 million. This suggests a slight increase in the operating shortfall for the current period. The company's CFO is working on implementing different corporate policies to ensure a steady revenue source.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com